Patents by Inventor Per-Mikael Aberg
Per-Mikael Aberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230347316Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.Type: ApplicationFiled: November 4, 2022Publication date: November 2, 2023Inventors: Martin HALL, Sture LARSSON, Andreas MURANYI, Gustav RODRIGO, Jinyu ZOU, Per-Mikael ABERG
-
Patent number: 11517879Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIF) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.Type: GrantFiled: November 30, 2020Date of Patent: December 6, 2022Assignee: CYTIVA BIOPROCESS R&D ABInventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg
-
Publication number: 20210291143Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIF) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.Type: ApplicationFiled: November 30, 2020Publication date: September 23, 2021Inventors: Martin HALL, Sture LARSSON, Andreas MURANYI, Gustav RODRIGO, Jinyu ZOU, Per-Mikael ABERG
-
Patent number: 10875007Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.Type: GrantFiled: June 17, 2019Date of Patent: December 29, 2020Assignee: CYTIVA BIOPROCESS R&D ABInventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg
-
Publication number: 20190308168Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.Type: ApplicationFiled: June 17, 2019Publication date: October 10, 2019Inventors: Martin HALL, Sture LARSSON, Andreas MURANYI, Gustav RODRIGO, Jinyu ZOU, Per-Mikael ABERG
-
Patent number: 10343142Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.Type: GrantFiled: November 13, 2018Date of Patent: July 9, 2019Assignee: GE HEALTHCARE BIOPROCESS R&D ABInventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg
-
Publication number: 20190060869Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.Type: ApplicationFiled: November 13, 2018Publication date: February 28, 2019Applicant: GE Healthcare BioProcess R&D ABInventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg
-
Patent number: 10213765Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.Type: GrantFiled: May 23, 2017Date of Patent: February 26, 2019Assignee: GE Healthcare Bioprocess R&DInventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg
-
Patent number: 10189891Abstract: The invention discloses an immunoglobulin-binding protein comprising one or more mutated immunoglobulin-binding domains (monomers) of staphylococcal Protein A (E, D, A, B, C) or protein Z or a functional variant thereof, wherein in at least one of the one or more mutated monomers, the asparagine or histidine at the position corresponding to H18 of the B domain of Protein A or of Protein Z has been deleted or substituted with a first amino acid residue which is not proline or asparagine and wherein, if the amino acid residue at position 57 is proline and the amino acid residue at position 28 is asparagine, then the amino acid residue at the position corresponding to H18 of the B domain of protein A or of protein Z is not serine, threonine or lysine.Type: GrantFiled: March 26, 2013Date of Patent: January 29, 2019Assignee: GE Healthcare BioProcess R&D ABInventors: Mats Ander, Goran Bauren, Tomas Bjorkman, Per-Mikael Aberg, Gustav Rodrigo
-
Publication number: 20170259244Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIF) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.Type: ApplicationFiled: May 23, 2017Publication date: September 14, 2017Applicant: GE Healthcare BioProcess R&D ABInventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg
-
Patent number: 9663559Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.Type: GrantFiled: March 7, 2016Date of Patent: May 30, 2017Assignee: GE Healthcare Bio-Sciences ABInventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg
-
Publication number: 20160200797Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.Type: ApplicationFiled: March 7, 2016Publication date: July 14, 2016Inventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg
-
Patent number: 9290549Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.Type: GrantFiled: January 27, 2014Date of Patent: March 22, 2016Assignee: GE Healthcare Bio-Sciences ABInventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg
-
Patent number: 9187555Abstract: The present invention relates to a method of separating one or more immunoglobulin containing proteins from a liquid. The method includes first contacting the liquid with a separation matrix comprising ligands immobilized to a support; allowing the immunoglobulin containing proteins to adsorb to the matrix by interaction with the ligands; followed by an optional step of washing the matrix containing the immunoglobulin containing proteins adsorbed thereon; and recovering said immunoglobulin containing proteins by contacting the matrix with an eluent which releases the proteins.Type: GrantFiled: December 19, 2011Date of Patent: November 17, 2015Assignee: GE Healthcare Bio-Sciences ABInventors: Tomas Bjorkman, Bjorn Noren, Gustav Rodrigo, Jelena Vasic, Per-Mikael Aberg
-
Publication number: 20150080554Abstract: The invention discloses an immunoglobulin-binding protein comprising one or more mutated immunoglobulin-binding domains (monomers) of staphylococcal Protein A (E, D, A, B, C) or protein Z or a functional variant thereof, wherein in at least one of the one or more mutated monomers, the asparagine or histidine at the position corresponding to H18 of the B domain of Protein A or of Protein Z has been deleted or substituted with a first amino acid residue which is not proline or asparagine and wherein, if the amino acid residue at position 57 is proline and the amino acid residue at position 28 is asparagine, then the amino acid residue at the position corresponding to H18 of the B domain of protein A or of protein Z is not serine, threonine or lysine.Type: ApplicationFiled: March 26, 2013Publication date: March 19, 2015Applicant: GE HEALTHCARE BIO-SCIENCES ABInventors: Mats Ander, Goran Bauren, Tomas Bjorkman, Per-Mikael Aberg, Gustav Rodrigo
-
Patent number: 8772447Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.Type: GrantFiled: July 27, 2012Date of Patent: July 8, 2014Assignee: GE Healthcare Bio-Sciences ABInventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg
-
Patent number: 8728828Abstract: The present invention relates to a separation matrix comprised of porous particles to which antibody-binding protein ligands have been immobilized, wherein the ligand density is in the range of 5.0-10 mg/ml; the gel phase distribution coefficient of the particles expressed as Kav for a dextran of size 110 kDa is above 0.65 and the median particle diameter is between 65-84 ?m. The carbohydrate material is preferably highly cross-linked agarose.Type: GrantFiled: December 22, 2005Date of Patent: May 20, 2014Assignee: GE Healthcare Bio-Sciences ABInventors: Hans Berg, Hans Johansson, Gunnar Malmquist, Per-Mikael Aberg
-
Publication number: 20140135476Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.Type: ApplicationFiled: January 27, 2014Publication date: May 15, 2014Applicant: GE HEALTHCARE BIO-SCIENCES ABInventors: MARTIN HALL, STURE LARSSON, ANDREAS MURANYI, GUSTAV RODRIGO, JINYU ZOU, PER-MIKAEL ABERG
-
Publication number: 20130338339Abstract: The present invention relates to a method of separating one or more immunoglobulin containing proteins from a liquid. The method includes first contacting the liquid with a separation matrix comprising ligands immobilised to a support; allowing the immunoglobulin containing proteins to adsorb to the matrix by interaction with the ligands; followed by an optional step of washing the matrix containing the immunoglobulin containing proteins adsorbed thereon; and recovering said immunoglobulin containing proteins by contacting the matrix with an eluent which releases the proteins.Type: ApplicationFiled: December 19, 2011Publication date: December 19, 2013Applicant: GE HEALTHCARE BIO-SCIENCES ABInventors: Tomas Bjorkman, Bjorn Noren, Gustav Rodrigo, Jelena Vasic, Per-Mikael Aberg
-
Patent number: 8329860Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIP) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates to a process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.Type: GrantFiled: September 27, 2007Date of Patent: December 11, 2012Assignee: GE Healthcare Bio-Sciences ABInventors: Martin Hall, Sture Larsson, Andreas Muranyi, Gustav Rodrigo, Jinyu Zou, Per-Mikael Aberg